Solid Biosciences and its subsidiary, Solid GT, announced today that the FDA and the European Commission have granted Orphan Drug designations for the company’s gene therapy candidate, SGT-001, for the treatment of people with Duchenne. Solid plans to initiate clinical studies for SGT-001 in 2017. Read the announcement from Solid:  Solid Biosciences Granted U.S. and E.U. Orphan Drug Designati…